1
|
Lu S, Yu Y, Zhou J, Goto K, Li X, Sakakibara-Konishi J, Nishino K, Kentaro T, Wu L, Min X, Zhang W, Huang D, Shu Y, Zhou C, Li M, Dong X, Bai C, Li L, Cui J, Zhang L, Cao L, Li X, Zang A, Kobayashi H, Zhang Y, Yu Y, Wang X, Kato T, Yamamoto S, Shinno Y, Lin X, Zhao Y, Hu Y, Yu Q, Wang Z, Kodani M, Fang J, Wang J, Shi M, Zhong D, Dong W, Tanaka H, Yoneshima Y, Sun M, Zhou J, Wu Q, Li M. Abstract CT034: Phase II study of SCC244 in NSCLC patients harboring MET exon 14 skipping (METex14) mutations (GLORY study). Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-ct034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: METex14 mutations was reported in 3~4% of NSCLC patients and became a new target in the treatment of NSCLC. SCC244 is a highly selective and potent oral MET inhibitor. This is the first report of data from an ongoing single-arm phase II study of SCC244 in NSCLC patients with METex14 mutations (GLORY study).
Methods: GLORY study is an open label, international, multi-center, single-arm phase II study to evaluate the efficacy and safety of SCC244 in patients with locally advanced or metastatic NSCLC harboring METex14 mutations which was confirmed by central laboratory. The enrolled patients have either failed one or two prior lines of systemic therapies or been not eligible/refused chemotherapy after being well-informed. SCC244 was taken orally at a dose of 300 mg once daily in 21-day treatment cycles until disease progression or intolerable toxicity. Tumor was evaluated every 6 weeks for the first 8 treatment cycles and every 9 weeks thereafter. The primary endpoint was objective response rate (ORR) assessed by blinded independent review committee (BIRC) per RECIST 1.1, secondary endpoints include ORR by investigator assessment (INV), duration of response (DoR), time to response (TTR) and safety etc. Post-hoc analysis was done to explore the intracranial anti-tumor activity.
Results: At data cut-off on May 6th, 2021, a total 73 patients screened from 163 patients in 42 sites were treated at 300 mg QD dose and had ≥2 post-baseline tumor assessments or discontinued for any reason. 69 of them were with METex14 mutation confirmed by central laboratory. In the 69 patients, ORR by BIRC was 60.9% (95% CI: 48.4%, 72.4%) overall, 66.7% (95% CI: 50.5, 80.4) and 51.9% (95% CI: 31.9, 71.3) in treatment naïve and previously treated patients respectively. Median DoR was 8.2 months (95% CI: 4.8, NE) and median PFS was 7.6 months (95% CI: 4.2, NE), tumor response from 30 of 42 responders was still ongoing. The response occurred fast with a median TTR of 1.4 months (range: 1.2, 4.2). Partial response was observed in 8 of 10 patients with brain metastasis. 5 patients who had brain metastasis selected as targeted lesion had intracranial response by INV with a median intracranial tumor shrinkage of 57% (range: 34%, 71%). The most common (≥20%) treatment-related adverse events (TRAEs) of any grade were peripheral edema, headache, nausea, loss of appetite, hypoalbuminemia, ALT increase and vomiting. The incidence of ≥ grade 3 TRAEs was 43.8%. TRAEs leading to treatment discontinuation occurred in 6.8% patients, among which peripheral edema was the most common (4.1%).
Conclusions: The data shows high and robust efficacy of SCC244 in NSCLC patients with METex14 mutations across treatment lines and encouraging intracranial anti-tumor activity. The safety profile was favorable with manageable toxicity. The data supports SCC244 as a valuable targeted treatment option for METex14 NSCLC patients.
Citation Format: Shun Lu, Yongfeng Yu, Jianya Zhou, Koichi Goto, Xingya Li, Jun Sakakibara-Konishi, Kazumi Nishino, Tanaka Kentaro, Lin Wu, Xuhong Min, Wei Zhang, Dingzhi Huang, Yongqian Shu, Chengzhi Zhou, Min Li, Xiaorong Dong, Chong Bai, Lu Li, Jiuwei Cui, Li Zhang, Lejie Cao, Xiaoling Li, AiMin Zang, Haruki Kobayashi, Yiping Zhang, Yan Yu, Xiuwen Wang, Terufumi Kato, Shoichiro Yamamoto, Yuki Shinno, Xiaoyan Lin, Yanqiu Zhao, Yanping Hu, Qitao Yu, Ziping Wang, Masahiro Kodani, Jian Fang, Jialei Wang, Meiqi Shi, Diansheng Zhong, Wen Dong, Hiroshi Tanaka, Yasuto Yoneshima, Minghui Sun, Jun Zhou, Qiuxia Wu, Meng Li. Phase II study of SCC244 in NSCLC patients harboring MET exon 14 skipping (METex14) mutations (GLORY study) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr CT034.
Collapse
Affiliation(s)
- Shun Lu
- 1Shanghai Chest Hopital, Shanghai, China
| | | | - Jianya Zhou
- 2The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
| | - Koichi Goto
- 3National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - Xingya Li
- 4The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | | | | | | | - Lin Wu
- 8Hunan Provincial Tumor Hospital, Changsha, China
| | - Xuhong Min
- 9Chest Hospital of Anhui Province, Hefei, China
| | - Wei Zhang
- 10First Affiliated Hospital of Nanchang University, Nanchang, China
| | | | | | - Chengzhi Zhou
- 13The First Affiliate Hospital of Guangzhou Medical University, Guangzhou, China
| | - Min Li
- 14Xiangya Hospital of Central South University, Changsha, China
| | - Xiaorong Dong
- 15Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Chong Bai
- 16Second Military Medical University, Shanghai, China
| | - Lu Li
- 17West China Hospital of Sichuan University, Chengdu, China
| | - Jiuwei Cui
- 18The First Hospital of Jilin University, Changchun, China
| | - Li Zhang
- 19Peking Union Medical College Hospital, Beijing, China
| | - Lejie Cao
- 20Anhui Provincial Hospital, Hefei, China
| | - Xiaoling Li
- 21Liaoning Cancer Hospital & Institute, Shenyang, China
| | - AiMin Zang
- 22Affiliated Hospital of Hebei University, Baoding, China
| | | | | | - Yan Yu
- 25Harbin Medical University Cancer Hospital, Harbin, China
| | - Xiuwen Wang
- 26Shandong University Qilu Hospital, Jinan, China
| | | | | | - Yuki Shinno
- 29National Cancer Center Hospital, Tokyo, Japan
| | - Xiaoyan Lin
- 30Fujian Medical University Union Hospital, Fuzhou, China
| | - Yanqiu Zhao
- 31Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
| | | | - Qitao Yu
- 33Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China
| | | | | | - Jian Fang
- 34Beijing cancer hospital, Beijing, China
| | - Jialei Wang
- 36Fudan University Shanghai Cancer Center, Shanghai, China
| | - Meiqi Shi
- 12Jiangsu Province Hospital, Nanjing, China
| | - Diansheng Zhong
- 37Tianjin Medical University General Hospital, Tianjin, China
| | - Wen Dong
- 38Hainan Cancer Hospital, Haikou, China
| | | | | | - Minghui Sun
- 40Haihe Biopharma Co., Ltd., Shanghai, China
| | - Jun Zhou
- 40Haihe Biopharma Co., Ltd., Shanghai, China
| | - Qiuxia Wu
- 40Haihe Biopharma Co., Ltd., Shanghai, China
| | - Meng Li
- 40Haihe Biopharma Co., Ltd., Shanghai, China
| |
Collapse
|